金城醫藥(300233.SZ):海通資管累計減持540.03萬股 減持計劃數量已過半
格隆匯10月23日丨金城醫藥(300233.SZ)公佈,2019年10月23日,公司收到海通資管出具的《股份減持計劃總實施進展告知函》,獲悉其管理的“海通證券資管-工商銀行-海通投融寶1號集合資產管理計劃”(“投融寶1號”)、“海通證券資管-工商銀行-海通海豐101號集合資產管理計劃”(“海通海豐101”)及“海通證券資管-工商銀行-海通海豐103號集合資產管理計劃”(“海通海豐103”)於2019年9月18日至2019年10月22日通過集中競價交易及大宗交易方式合計減持公司股份約540.03萬股,佔公司總股本的1.385%。截至2019年10月22日,海通資管減持公司股份數量較其預披露減持計劃數量已過半。
此次減持後,海通資管持股比例由7.798%降至6.413%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.